Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGES | O14684 | 15/20 | 0.57 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.47 |
| ▸ | CA1 | P00915 | 1/20 | 0.46 |
| ▸ | CA2 | P00918 | 1/20 | 0.46 |
| ▸ | CA7 | P43166 | 1/20 | 0.46 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.46 |
| ▸ | TSHR | P16473 | 1/20 | 0.46 |
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.44 |
| ▸ | F2R | P25116 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1671704 | 0.89 | PTGES (0.59) | PTGESHDAC6CA1CA2CA7 | |
| SCHEMBL16671026 | 0.86 | PTGES (0.59) | PTGESHDAC6CA1CA2CA7 | |
| SCHEMBL17199049 | 0.86 | PTGES (0.59) | PTGESHDAC6CA1CA2CA7 | |
| SCHEMBL10046412 | 0.84 | PTGES (0.58) | PTGESHDAC6CA1CA2CA7 | |
| SCHEMBL18523460 | 0.84 | PTGES (0.55) | PTGESHDAC6CA1CA2CA7 | |
| SCHEMBL9932144 | 0.83 | PTGES (0.57) | PTGESHDAC6CA1CA2CA7 | |
| SCHEMBL18810196 | 0.82 | PTGES (0.56) | PTGESHDAC6CA1CA2CA7 | |
| SCHEMBL20551176 | 0.82 | PTGES (0.56) | PTGESHDAC6CA1CA2CA7 | |
| Hydrochloric Acid SCHEMBL29417239 | 0.81 | PTGES (0.55) | PTGESHDAC6CA1CA2CA7 | |
| Hydrochloric Acid SCHEMBL20489802 | 0.81 | PTGES (0.55) | PTGESHDAC6CA1CA2CA7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170037044-A1 | AMIDE DERIVATIVES AND PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF, PREPARATION METHOD THEREOF AND MEDICINAL APPLICATION THEREOF | SHANGHAI HENGRUI PHARMACEUTICAL CO., LTD. (CN) | 2017-02-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170037044-A1 | AMIDE DERIVATIVES AND PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF, PREPARATION METHOD THEREOF AND MEDICINAL APPLICATION THEREOF | PTGES, PTGS1, PTGIS | PTGES 1/4885HDAC6 1366/4885CA1 3222/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.